To capture the treatment patterns and clinical characteristics of patients with ER/PR positive, HER2-negative MBC in Greece~To evaluate the outcome of patients per treatment line (objective response, progression free survival, time to disease progression per line of therapy), overall survival~To record adverse events per line of therapy~To recording of the causes of treatment discontinuation per line of therapy
• To capture the treatment patterns and clinical characteristics of patients with ER/PR positive, HER2-negative MBC in Greece